Munich Cancer Registry



- ▶ Baseline statistics
- ▶ Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

C32, C10.1: Larynx cancer

Year of diagnosis	1978-1987	1988-1997	1998-2011
Patients	428	826	1,886
Diseases	429	826	1,889
Creation date	04/01/2013		
Export date	01/03/2013		
Population	4.5 m		



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C32__E.pdf




Figure 1a. Relative survival of patients with larynx cancer by period of diagnosis. Included in the evaluation are 2,144 cases diagnosed between 1978 and 2011.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.



Period of diagnosis												
	1978-	1987	1988-	1997	1998+							
	n=3	880	n=7	' 19	n=1,045							
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %						
0	100.0	100.0	100.0	100.0	100.0	100.0						
1	88.2	90.9	87.9	90.0	87.3	89.1						
2	76.5	81.2	76.7	80.5	77.0	80.2						
3	68.6	74.8	69.0	74.0	68.9	73.3						
4	64.8	72.3	62.5	68.7	64.1	69.8						
5	60.0	69.2	57.2	64.5	59.0	65.6						
6	55.8	66.2	51.6	59.8	53.5	60.9						
7	50.7	62.0	48.2	57.3	49.5	57.4						
8	48.3	60.7	45.0	54.7	46.0	55.0						
9	45.1	58.2	41.9	52.0	43.0	52.7						
10	41.8	55.5	40.0	51.0	39.4	49.8						
11	40.2	54.7	36.9	48.2	36.1	46.7						
12	36.2	50.8	34.8	46.6	33.5	44.3						
13	33.8	49.0	31.3	43.0	32.3	44.0						
14	31.1	46.2	28.7	40.5								
15	29.5	45.1	26.5	38.5								
16	26.8	42.4	23.1	34.5								
17	25.4	41.4	20.4	31.5								
18	24.1	40.6	17.6	28.0								
19	21.1	36.6	16.3	26.6								
20	18.9	34.2	15.7	25.9								

Table 1b. Observed (obs.) and relative (rel.) survival of patients with larynx cancer by period of diagnosis for period 1978-2011 (N=2,144).




Figure 2a. Survival of patients with larynx cancer by gender. Included in the evaluation are 1,764 cases diagnosed between 1988 and 2011.

Munich Cancer Registry 04/01/2013 surv_C32__E.pdf

Gender											
	Ma	ale	Female								
	n=1,	547	n=217								
Years	obs. %	rel. %	obs. %	rel. %							
0	100.0	100.0	100.0	100.0							
1	87.8	89.8	86.0	87.3							
2	76.8	80.3	77.6	80.2							
3	68.7	73.6	70.4	74.0							
4	63.0	69.1	65.9	70.6							
5	57.8	64.9	60.5	65.8							
6	52.5	60.5	53.0	59.2							
7	48.9	57.7	49.2	55.7							
8	45.4	55.0	47.6	54.2							
9	42.6	52.7	42.3	49.3							
10	40.1	51.2	41.3	48.7							
11	36.9	48.4	37.9	46.1							
12	34.8	46.9	34.1	42.2							
13	31.8	44.0	29.1	37.1							
14	29.1	41.2	29.1	35.9							
15	26.9	39.3									
16	23.3	35.2									
17	20.3	31.7									
18	17.3	27.8									
19	15.8	26.0									
20	15.1	25.1									

Table 2b. Observed (obs.) and relative (rel.) survival of patients with larynx cancer by gender for period 1988-2011 (N=1,764).




Figure 3a. Relative survival of patients with larynx cancer by age category. Included in the evaluation are 1,764 cases diagnosed between 1988 and 2011.

Munich Cancer Registry 04/01/2013 surv_C32__E.pdf

	Age category												
	0-49	yrs	50-59	9 yrs	60-69	9 yrs	70+	yrs					
	n=2	225	n=5	550	n=600		n=3	389					
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %					
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0					
1	93.3	93.2	89.3	89.8	86.8	88.4	82.9	88.1					
2	83.5	84.1	78.3	79.4	76.5	79.3	71.6	81.0					
3	77.8	78.3	70.7	72.3	68.8	72.8	61.3	74.1					
4	73.3	74.0	66.8	69.2	61.5	66.5	55.0	71.3					
5	67.8	68.8	62.5	65.2	56.0	62.0	48.9	67.7					
6	64.8	66.1	57.4	60.6	50.5	57.6	40.9	62.1					
7	62.2	63.6	55.0	58.6	47.1	55.1	34.2	56.8					
8	60.7	62.0	51.8	56.1	43.7	52.7	29.8	53.6					
9	60.0	61.9	49.4	54.2	39.7	49.5	25.6	49.2					
10	59.2	61.6	47.6	53.0	37.8	48.7	20.8	45.0					
11	56.7	59.8	44.3	50.0	34.2	46.0	17.8	42.1					
12	55.9	59.2	41.6	47.5	32.6	46.0	14.0	36.3					
13	53.1	56.0	38.2	44.5	29.5	43.3							
14	48.0	51.0	35.5	42.0	27.4	42.5							
15	45.6	49.6	32.8	39.5	25.1	40.6							
16	45.6	49.2	27.3	34.1	20.6	35.1							
17	45.6	48.9	23.3	29.4	16.3	30.1							
18	43.6	47.9	20.7	25.8									
19	43.6	46.7											
20	43.6	45.4											

Table 3b. Observed (obs.) and relative (rel.) survival of patients with larynx cancer by age category for period 1988-2011 (N=1,764).




Figure 4a. Relative survival of patients with larynx cancer by TNM staging. For 1,630 of 1,764 cases diagnosed between 1988 and 2011 valid data could be obtained for this item. For a total of 1,625 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 139 patients with missing values regarding TNM staging (7.9% of 1,764 patients, the percent values of all other categories are related to n=1,625).

	TNM staging													
	Т	1	Т	2	T3	+4	N	0	N	+	N	X	NA/NOS	
	n=6	640	n=3	333	n=6	35	n=1,089		n=4	115	n=	60	n=139	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.7	99.0	93.3	95.2	77.4	78.9	93.1	95.2	76.7	77.8	79.8	80.7	78.2	79.7
2	91.5	95.9	81.3	84.7	60.4	62.7	85.6	89.7	54.0	55.7	71.8	74.7	73.0	76.7
3	86.6	93.0	72.4	76.7	50.1	52.9	79.6	85.3	40.9	42.9	65.2	68.8	63.4	68.6
4	81.2	89.6	68.0	73.8	43.8	47.1	74.4	81.6	34.3	36.5	60.4	64.2	56.8	62.8
5	76.7	86.7	60.8	67.3	39.0	42.7	69.2	77.6	30.1	32.3	54.9	61.1	50.6	57.9
6	69.8	81.2	55.0	62.3	35.3	39.3	63.5	73.2	25.3	27.6	54.9	61.1	44.1	51.8
7	66.0	78.5	51.4	59.5	32.4	36.8	59.3	69.9	22.5	25.1	54.9	61.1	39.8	48.7
8	62.5	76.4	45.8	54.2	29.6	34.3	54.5	65.9	22.0	24.5	54.9	61.1	39.8	48.7
9	59.5	74.5	42.1	51.3	26.7	31.6	51.3	63.4	19.0	21.8			37.4	48.2
10	57.2	73.7	39.5	49.3	24.3	29.3	48.8	62.0	17.4	20.0			36.1	47.6

Table 4b. Observed (obs.) and relative (rel.) survival of patients with larynx cancer by TNM staging for period 1988-2011 (N=3,172).




Figure 4c. Relative survival of patients with larynx cancer by TNM staging. For 966 of 1,045 cases diagnosed between 1998 and 2011 valid data could be obtained for this item. For a total of 962 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 83 patients with missing values regarding TNM staging (7.9% of 1,045 patients, the percent values of all other categories are related to n=962).

	TNM staging													
	Т	1	Т	2	T3	+4	N	NO N		+	N	Χ	NA/NOS	
	n=3	392	n=2	203	n=3	357	n=623		n=2	243	n=50		n=83	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.9	98.8	95.0	96.7	76.1	77.4	94.0	95.9	76.6	77.6	77.7	78.5	71.8	73.1
2	92.5	96.7	82.2	84.4	58.7	60.9	87.0	90.8	54.0	55.3	70.2	73.3	66.6	69.7
3	87.3	93.1	73.2	77.0	48.2	50.7	80.4	85.7	40.6	42.5	67.4	71.1	56.3	60.2
4	82.3	90.2	69.7	74.9	42.9	45.9	75.2	81.9	36.9	38.9	64.4	68.2	51.5	55.5
5	77.2	86.7	64.1	70.2	37.9	40.9	70.2	78.2	31.6	33.4	57.3	64.1	46.3	51.3
6	70.8	81.5	56.2	62.5	35.0	38.7	64.4	73.3	27.0	29.4	57.3	64.1	40.5	46.3
7	67.4	79.0	52.5	59.5	30.9	34.6	59.6	69.2	22.5	24.7	57.3	64.1		
8	62.3	75.7	49.0	56.7	28.5	32.7	54.6	65.5			57.3	64.1		
9	59.2	73.7	42.7	50.9	26.4	30.1	51.7	63.1						
10	55.9	72.1	40.0	48.6			48.7	61.3						

Table 4d. Observed (obs.) and relative (rel.) survival of patients with larynx cancer by TNM staging for period 1998-2011 (N=1,868).




Figure 4e. Conditional relative 2-year survival of patients with larynx cancer by extent of disease. For 1,630 of 1,764 cases diagnosed between 1988 and 2011 valid data could be obtained for this item. For a total of 1,249 cases an evaluable classification was established. The grey line represents the subgroup of 515 patients with missing values regarding extent of disease (29.2% of 1,764 patients, the percent values of all other categories are related to n=1,249).

	Extent of disease														
	Loc	al	Regio	onal	Dist	ant	NA/NOS								
		Cond.	Cond.		Cond.			Cond.							
		surv. %		surv. %		surv. %		surv. %							
Years	n	2 yrs	n	2 yrs	n	2 yrs	n	2 yrs							
0	930	90.0	292	59.2	27		515	77.1							
1	850	90.1	223	55.0			418	81.7							
2	750	91.9	147	61.9			336	85.7							
3	656	91.5	102	73.8			274	87.8							
4	576	89.0	77	81.4			221	87.1							
5	495	89.8	67	84.7			186	87.9							

Table 4f. Conditional relative 2-year survival of patients with larynx cancer by extent of disease for period 1988-2011 (N=1,249).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 91.5% (n=656).




Figure 5a. Observed post-progression survival of 560 patients with larynx cancer diagnosed between 1978 and 2011 (incl. M1). These 560 patients with documented progression events during their course of disease represent 26.1% of the totally 2,144 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=152, 7.1%). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The

NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	Type of progression											
	All types	Local relapse	NOS									
	n=560	n=329	n=177	n=379	n=119							
Months	%	%	%	%	%							
0	100.0	100.0	100.0	100.0	100.0							
12	58.8	65.0	27.7	64.1	62.5							
24	44.0	50.4	14.3	48.4	48.6							
36	37.8	44.1		42.6	41.1							
48	33.0	37.7		36.7	37.1							
60	29.4	33.9		33.3	32.4							

Table 5b. Observed post-progression survival of patients with larynx cancer for period 1978-2011 (N=560).



Shortcuts

AS Assembled survival chart (observed, expected, relative)

CS Conditional survival

DCO Death certificate only. The death certificate provides the only notification to the registry.

MCR Munich Cancer Registry, Germany (Tumorregister München)

NA Not available

NCI National Cancer Institute, USA

NOS Not otherwise specified

OS Observed/overall survival (Kaplan-Meier estimate)

PPS Post-progression survival

RS Relative Survival. Ratio of observed and expected survival (derived from the normal population)

SEER Surveillance, Epidemiology, and End Results, USA

TTP Time to progression

Date of entry: Date of diagnosis

Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified

recurrence

First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate).

First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where

applicable ("reverse" Kaplan-Meier estimate).

UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C32, C10.1: Larynx cancer [Internet]. 2013 [updated 2013 Apr 1; cited 2013 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C32__E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

F	ig./Tbl	l.	Page
	1a	Relative survival by period of diagnosis (chart)	2
	1b	Survival by period of diagnosis (table)	3
	2a	Survival by gender (chart)	3
	2b	Survival by gender (table)	4
	3a	Relative survival by age category (chart)	4
	3b	Survival by age category (table)	5
	4a	Relative survival by TNM staging 1988+ (chart)	5
	4b	Survival by TNM staging 1988+ (table)	6
	4c	Relative survival by TNM staging 1998+ (chart)	6
	4d	Survival by TNM staging 1998+ (table)	7
	4e	Conditional survival by extent of disease (chart)	7
	4f	Conditional survival by extent of disease (table)	8
	5a	Observed post-progression survival (chart)	8
	5b	Observed post-progression survival (table)	9